ArticleTrends in molecular medicine2025
NF2-associated schwannomatosis (NF2): genetics, manifestations, and emerging therapeutic approaches.
Osama Elzaafarany, Daniel Lester, Sepideh Mokhtari, Joseph L Kissil
Abstract read
In one paragraphArticle in Trends in molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
4 authors.
Osama ElzaafaranyDepartment of Neuro-oncology, The H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Daniel LesterDepartment of Molecular Oncology, The H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Sepideh MokhtariDepartment of Neuro-oncology, The H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Sepideh.Mokhtari@Moffitt.Org.
Joseph L KissilDepartment of Molecular Oncology, The H. Lee Moffitt Cancer Center, Tampa, FL, USA. Electronic address: Joseph.Kissil@Moffitt.Org.
Funding
CARM1-mediated regulation of YAP1 as a therapeutic target in lung cancerR01CA250276 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI KISSIL, JOSEPH · 2020 to 2024
$2.1MElucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targetsR01NS117926 · NINDS · H. LEE MOFFITT CANCER CTR & RES INST · PI KISSIL, JOSEPH · 2021 to 2024
$1.7MEmploying functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2R33NS119658 · NINDS · H. LEE MOFFITT CANCER CTR & RES INST · PI KISSIL, JOSEPH · 2023 to 2024
$827kElucidating the epigenetic landscape of neurofibromatosis and development of therapeutic targetsR56NS117926 · NINDS · SCRIPPS FLORIDA · PI KISSIL, JOSEPH · 2020 to 2020
$472kEmploying functionalized fragment libraries to identify therapeutic agents for neurofibromatosis type 2R61NS119658 · NINDS · SCRIPPS FLORIDA · PI KISSIL, JOSEPH · 2021 to 2021
$347kNCI NIH HHS R01 CA250276NINDS NIH HHS R01 NS117926NINDS NIH HHS R33 NS119658NINDS NIH HHS R56 NS117926NINDS NIH HHS R61 NS119658
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
MerlinNF2-associated schwannomatosisschwannoma
Identifiers
PMID40885618
PMCPMC12404673
What OpenQuestion holds
Textmetadata
Read underepoch 390